Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003010 · ClinicalTrials.gov registry record · Phase 3
Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 334
- Enrollment target
NCT00003010 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 334 participants.
The verdict
NCT00003010, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 334 participants
- Enrollment target
Study Summary
RATIONALE: Marimastat may stop the growth of breast cancer by stopping blood flow to the tumor. It is not known whether chemotherapy is more effective with or without marimastat for breast cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of marimastat with that of no further therapy in treating women who have metastatic breast cancer that is responding or stable after chemotherapy.
Interventions
- DRUG marimastat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 1997-12-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003010
The ClinicalTrials.gov registry entry for NCT00003010 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which marimastat is the first listed.
NCT00003010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003010 about?
NCT00003010 is a clinical study titled "Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy". RATIONALE: Marimastat may stop the growth of breast cancer by stopping blood flow to the tumor. It is not known whether chemotherapy is more effective with or without marimastat for breast cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of marimastat with tha...
What is the current status of trial NCT00003010?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 334 participants. The study started on 1997-12-02.
What interventions are being tested in trial NCT00003010?
The interventions under investigation include: marimastat (DRUG).
Who is sponsoring clinical trial NCT00003010?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.